Abstract
Migraine is a disabling and recurrent neurological disorder characterized by headache attacks that are often accompanied by sensory and motor disturbances. The value and importance of reliable biomarkers in migraine have been long recognized and a diverse range of biomarkers from biological samples to electrophysiological patterns and brain imaging has been proposed. There is still no consensus on specific biomarker(s) for migraine. Ideally, not a single but a battery of biomarkers would provide a multidisciplinary way to understand and treat migraine better. Translational research has witnessed an escalating number of studies on microRNAs (miRNAs) during the last decade. Identification of the first miRNA occurred in 1993, and currently more than 2000 human miRNAs have been recognized. miRNAs are a group of endogenous small non-coding molecules that play a key role in post-transcriptional gene processes and hence are involved in health and disease. miRNAs have already been found to be involved in the onset and progression of several human disorders including chronic pain conditions; however, there have been far fewer studies in migraine and other headaches. Current evidence does suggest that miRNAs play a role in migraine and its relief and hence these molecules are proposed as potential migraine biomarkers. This review updates the current evidence for the role of miRNAs in migraine; including their potential as biomarkers, with a role in understanding of its pathogenesis, the population at risk, diagnosis, patient stratification, chronification risk factors, response to treatments, and miRNA-based therapeutic options. Limitations exist and further research is required to completely unwrap the potential of miRNAs in migraine research and practice.
Similar content being viewed by others
References
Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50 s: will health politicians now take notice? J Headache Pain. 2018;19:17. https://doi.org/10.1186/s10194-018-0846-2.
Lanteri-Minet M. Economic burden and costs of chronic migraine. Curr Pain Headache Rep. 2013;18(1):385. https://doi.org/10.1007/s11916-013-0385-0.
Straube A, Andreou AP. Primary headaches during lifespan. J Headache Pain. 2019;20:71. https://doi.org/10.1186/s10194-019-1025-9.
Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and CrossMark pathophysiology of migraine. Lancet Neurol. 2017;16(1):76–87. https://doi.org/10.1016/S1474-4422(16)30293-9.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
Dodick DW. Migraine. Lancet. 2018;391(10127):1315–30. https://doi.org/10.1016/S0140-6736(18)30478-1.
Russo A, Silvestro M, Tessitore A, Tedeschi G. Recent insights in migraine with aura: a narrative review of advanced neuroimaging. Headache. 2019;59(4):637–49. https://doi.org/10.1111/head.13512.
Hadjikhani N, Vincent M. Neuroimaging clues of migraine aura. J Headache Pain. 2019;20:32. https://doi.org/10.1186/s10194-019-0983-2.
Manzoni GC, Torelli P. Migraine with and without aura: a single entity? Neurol Sci. 2008;29:S40–3. https://doi.org/10.1007/s10072-008-0884-7.
Russell MB, Ulrich V, Gervil M, Olesen J. Migraine without aura and migraine with aura are distinct disorders. A population-based twin survey. Headache. 2002;42(5):332–6. https://doi.org/10.1046/j.1526-4610.2002.02102.x.
Ligthart L, Boomsma DI, Martin NG, Stubbe JH, Nyholt DR. Migraine with aura and migraine without aura are not distinct entities: further evidence from a large Dutch population study. Twin Res Hum Genet. 2006;9(1):54–63. https://doi.org/10.1375/183242706776403019.
Viana M, Linde M, Sances G, Ghiotto N, Guaschino E, Allena M, et al. Migraine aura symptoms: duration, succession and temporal relationship to headache. Cephalalgia. 2016;36(5):413–21. https://doi.org/10.1177/0333102415593089.
Viana M, Tronvik EA, Do TP, Zecca C, Hougaard A. Clinical features of visual migraine aura: a systematic review. J Headache Pain. 2019;20:64. https://doi.org/10.1186/s10194-019-1008-x.
Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174–82. https://doi.org/10.1016/S1474-4422(17)30435-0.
Sutherland HG, Albury CL, Griffiths LR. Advances in genetics of migraine. J Headache Pain. 2019;20:72. https://doi.org/10.1186/s10194-019-1017-9.
Kondratieva N, Azimova J, Skorobogatykh K, Sergeev A, Naumova E, Kokaeva Z, et al. Biomarkers of migraine: part 1 - genetic markers. J Neurol Sci. 2016;369:63–76. https://doi.org/10.1016/j.jns.2016.08.008.
Gazerani P. Current evidence on the role of epigenetic mechanisms in migraine: the way forward to precision medicine. OBM Genet. 2018;2(4):040. https://doi.org/10.21926/obm.genet.1804040.
Eising E, Datson NA, van den Maagdenberg AMJM, Ferrari MD. Epigenetic mechanisms in migraine: a promising avenue? BMC Med. 2013;11:26. https://doi.org/10.1186/1741-7015-11-26.
Terlizzi R, Bacalini MG, Pirazzini C, Giannini G, Pierangeli G, Garagnani P, et al. Epigenetic DNA methylation changes in episodic and chronic migraine. Neurol Sci. 2018;39:S67–8. https://doi.org/10.1007/s10072-018-3348-8.
Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55 Suppl 2:103–22 (quiz 23–6). https://doi.org/10.1111/head.12505_2.
Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86–92. https://doi.org/10.1007/s11916-011-0233-z.
Zhang LM, Dong Z, Yu SY. Migraine in the era of precision medicine. Ann Transl Med. 2016;4(6):105. https://doi.org/10.21037/atm.2016.03.13.
Antonaci F, Ghiotto N, Wu SZ, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus. 2016;5:637. https://doi.org/10.1186/s40064-016-2211-8.
Gooriah R, Nimeri R, Ahmed F. Evidence-based treatments for adults with migraine. Pain Res Treat. 2015;2015:629382. https://doi.org/10.1155/2015/629382.
Scuteri D, Adornetto A, Rombola L, Naturale MD, Morrone LA, Bagetta G, et al. New trends in migraine pharmacology: targeting calcitonin gene-related peptide (CGRP) with monoclonal antibodies. Front Pharmacol. 2019;10:363. https://doi.org/10.3389/fphar.2019.00363.
Tringali G, Navarra P. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis. Peptides. 2019;116:16–21. https://doi.org/10.1016/j.peptides.2019.04.012.
Tepper SJ. History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. Headache. 2018;58:238–75. https://doi.org/10.1111/head.13379.
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142–9. https://doi.org/10.1056/NEJMoa1811090.
Moreno-Ajona D, Chan C, Villar-Martinez MD, Goadsby PJ. Targeting CGRP and 5-HT1F receptors for the acute therapy of migraine: a literature review. Headache. 2019;59(Suppl 2):3–19. https://doi.org/10.1111/head.13582.
Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019;28(6):555–67. https://doi.org/10.1080/13543784.2019.1618830.
Gallelli L, Cione E, Caroleo MC, Carotenuto M, Lagana P, Siniscalchi A, et al. microRNAs to monitor pain-migraine and drug treatment. Microrna. 2017;6(3):152–6. https://doi.org/10.2174/2211536606666170913152821.
Borsook D, Becerra L, Hargreaves R. Biomarkers for chronic pain and analgesia. Part 1: the need, reality, challenges, and solutions. Discov Med. 2011;11(58):197–207.
Borsook D, Becerra L, Hargreaves R. Biomarkers for chronic pain and analgesia. Part 2: how, where, and what to look for using functional imaging. Discov Med. 2011;11(58):209–19.
Durham P, Papapetropoulos S. Biomarkers associated with migraine and their potential role in migraine management. Headache. 2013;53(8):1262–77. https://doi.org/10.1111/head.12174.
Loder E, Graham JR. From subjective to objective: biomarkers in migraine. Headache. 2006;46(7):1045. https://doi.org/10.1111/j.1526-4610.2006.00497.x.
Kowalska M, Prendecki M, Kozubski W, Lianeri M, Dorszewska J. Molecular factors in migraine. Oncotarget. 2016;7(31):50708–18. https://doi.org/10.18632/oncotarget.9367.
Kowalska M, Kapelusiak-Pielok M, Grzelak T, Wypasek E, Kozubski W, Dorszewska J. The new *G29A and G1222A of HCRTR1, 5-HTTLPR of SLC6A4 Polymorphisms and hypocretin-1, serotonin concentrations in migraine patients. Front Mol Neurosci. 2018;11:191. https://doi.org/10.3389/fnmol.2018.00191.
Loder E, Rizzoli P. Biomarkers in migraine: their promise, problems, and practical applications. Headache. 2006;46(7):1046–58. https://doi.org/10.1111/j.1526-4610.2006.00498.x.
Loder E, Harrington MG, Cutrer M, Sandor P, De Vries B. Selected confirmed, probable, and exploratory migraine biomarkers. Headache. 2006;46(7):1108–27. https://doi.org/10.1111/j.1526-4610.2006.00525.x.
Califf RM. Biomarker definitions and their applications. Exp Biol Med. 2018;243(3):213–21. https://doi.org/10.1177/1535370217750088.
Neuroscience biomarkers and biosignatures: converging technologies, emerging partnerships, workshop summary. The National Academies Collection: reports funded by National Institutes of Health. Washington, DC: The National Academies Press; 2008.
Belvís R, Pozo-Rosich P, Pascual J. New insights into diagnostic biomarkers of migraine: biological, genetic and radiological. Int J Neuro Disord Interv. 2015;1:105. https://doi.org/10.15344/ijndi/2015/105.
Drucker E, Krapfenbauer K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J. 2013;4(1):7. https://doi.org/10.1186/1878-5085-4-7.
Mayeux R. Biomarkers: potential uses and limitations. NeuroRx. 2004;1(2):182–8. https://doi.org/10.1602/neurorx.1.2.182.
Casteleyn L, Dumez B, Van Damme K, Anwar WA. Ethics and data protection in human biomarker studies in environmental health. Int J Hyg Envir Heal. 2013;216(5):599–605. https://doi.org/10.1016/j.ijheh.2013.03.016.
Coppola L, Cianflone A, Grimaldi AM, Incoronato M, Bevilacqua P, Messina F, et al. Biobanking in health care: evolution and future directions. J Transl Med. 2019;17:172. https://doi.org/10.1186/s12967-019-1922-3.
Kuzhandai Velu V, Ramesh R, Srinivasan AR. Circulating MicroRNAs as biomarkers in health and disease. J Clin Diagn Res. 2012;6(10):1791–5. https://doi.org/10.7860/JCDR/2012/4901.2653.
Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–74. https://doi.org/10.1038/nrg3074.
Backes C, Meese E, Keller A. Specific miRNA disease biomarkers in blood, serum and plasma: challenges and prospects. Mol Diagn Ther. 2016;20(6):509–18. https://doi.org/10.1007/s40291-016-0221-4.
Trzybulska D, Vergadi E, Tsatsanis C. miRNA and other non-coding RNAs as promising diagnostic markers. EJIFCC. 2018;29(3):221–6.
Wei JW, Huang K, Yang C, Kang CS. Non-coding RNAs as regulators in epigenetics. Oncol Rep. 2017;37(1):3–9. https://doi.org/10.3892/or.2016.5236.
Camara MS, Martin Bujanda M, Mendioroz Iriarte M. Epigenetic changes in headache. Neurologia Epub. 2017. https://doi.org/10.1016/j.nrl.2017.10.010.
Kreth S, Hubner M, Hinske LC. MicroRNAs as clinical biomarkers and therapeutic tools in perioperative medicine. Anesth Analg. 2018;126(2):670–81. https://doi.org/10.1213/Ane.0000000000002444.
Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW, et al. The microRNAs of Caenorhabditis elegans. Gene Dev. 2003;17(8):991–1008. https://doi.org/10.1101/gad.1074403.
O’Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. 2018;9:402. https://doi.org/10.3389/fendo.2018.00402.
Coenen-Stass AML, Magen I, Brooks T, Ben-Dov IZ, Greensmith L, Hornstein E, et al. Evaluation of methodologies for microRNA biomarker detection by next generation sequencing. RNA Biol. 2018;15(8):1133–45. https://doi.org/10.1080/15476286.2018.1514236.
Li Y, Kowdley KV. MicroRNAs in common human diseases. Genom Proteom Bioinform. 2012;10(5):246–53. https://doi.org/10.1016/j.gpb.2012.07.005.
Kandhro AH. MicroRNAs from diagnosis to therapy: future perspective. Transl Biomed. 2016. https://doi.org/10.2167/2172-0479.100089.
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20. https://doi.org/10.1016/j.cell.2004.12.035.
Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019;47(D1):D155–62. https://doi.org/10.1093/nar/gky1141.
Alles J, Fehlmann T, Fischer U, Backes C, Galata V, Minet M, et al. An estimate of the total number of true human miRNAs. Nucleic Acids Res. 2019;47(7):3353–64. https://doi.org/10.1093/nar/gkz097.
Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33. https://doi.org/10.1016/j.cell.2009.01.002.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97. https://doi.org/10.1016/S0092-8674(04)00045-5.
Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12(11):847–65. https://doi.org/10.1038/nrd4140.
Osman A. MicroRNAs in health and disease—basic science and clinical applications. Clin Lab. 2012;58(5–6):393–402.
Ardekani AM, Naeini MM. The role of microRNAs in human diseases. Avicenna J Med Biotechnol. 2010;2(4):161–79.
Tufekci KU, Oner MG, Meuwissen RL, Genc S. The role of microRNAs in human diseases. Methods Mol Biol. 2014;1107:33–50. https://doi.org/10.1007/978-1-62703-748-8_3.
Treiber T, Treiber N, Meister G. Author correction: regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol. 2018;19(12):808. https://doi.org/10.1038/s41580-018-0070-6.
Ma YH. The challenge of microRNA as a biomarker of epilepsy. Curr Neuropharmacol. 2018;16(1):37–42. https://doi.org/10.2174/1570159x15666170703102410.
Swarbrick S, Wragg N, Ghosh S, Stolzing A. Systematic review of miRNA as biomarkers in Alzheimer’s disease. Mol Neurobiol. 2019;56(9):6156–67. https://doi.org/10.1007/s12035-019-1500-y.
Zhou SS, Jin JP, Wang JQ, Zhang ZG, Freedman JH, Zheng Y, et al. miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges. Acta Pharmacol Sin. 2018;39(7):1073–84. https://doi.org/10.1038/aps.2018.30.
Ojha R, Nandani R, Pandey RK, Mishra A, Prajapati VK. Emerging role of circulating microRNA in the diagnosis of human infectious diseases. J Cell Physiol. 2019;234(2):1030–43. https://doi.org/10.1002/jcp.27127.
Tana C, Giamberardino MA, Cipollone F. microRNA profiling in atherosclerosis, diabetes, and migraine. Ann Med. 2017;49(2):93–105. https://doi.org/10.1080/07853890.2016.1226515.
Slota JA, Booth SA. MicroRNAs in Neuroinflammation: implications in disease pathogenesis, biomarker discovery and therapeutic applications. Noncoding RNA. 2019;5(2):E35. https://doi.org/10.3390/ncrna5020035.
Gambari R, Fabbri E, Borgatti M, Lampronti I, Finotti A, Brognara E, et al. Targeting microRNAs involved in human diseases: a novel approach for modification of gene expression and drug development. Biochem Pharmacol. 2011;82(10):1416–29. https://doi.org/10.1016/j.bcp.2011.08.007.
Hanna J, Hossain GS, Kocerha J. The potential for microRNA therapeutics and clinical research. Front Genet. 2019;10:478. https://doi.org/10.3389/fgene.2019.00478.
Lopez-Gonzalez MJ, Landry M, Favereaux A. MicroRNA and chronic pain: from mechanisms to therapeutic potential. Pharmacol Ther. 2017;180:1–15. https://doi.org/10.1016/j.pharmthera.2017.06.001.
Andersen HH, Duroux M, Gazerani P. MicroRNAs as modulators and biomarkers of inflammatory and neuropathic pain conditions. Neurobiol Dis. 2014;71:159–68. https://doi.org/10.1016/j.nbd.2014.08.003.
Dayer CF, Luthi F, Le Carre J, Vuistiner P, Terrier P, Benaim C, et al. Differences in the miRNA signatures of chronic musculoskeletal pain patients from neuropathic or nociceptive origins. PLoS One. 2019;14(7):e0219311. https://doi.org/10.1371/journal.pone.0219311.
Ramanathan S, Ajit SK. MicroRNA-based biomarkers in pain. Adv Pharmacol. 2016;75:35–62. https://doi.org/10.1016/bs.apha.2015.12.001.
McDonald MK, Ajit SK. MicroRNA biology and pain. Prog Mol Biol Transl Sci. 2015;131:215–49. https://doi.org/10.1016/bs.pmbts.2014.11.015.
Orlova IA, Alexander GM, Qureshi RA, Sacan A, Graziano A, Barrett JE, et al. MicroRNA modulation in complex regional pain syndrome. J Transl Med. 2011;9:195. https://doi.org/10.1186/1479-5876-9-195.
Zhai Y, Zhu YY. MiR-30a relieves migraine by degrading CALCA. Eur Rev Med Pharmacol Sci. 2018;22(7):2022–8.
Tafuri E, Santovito D, de Nardis V, Marcantonio P, Paganelli C, Affaitati G, et al. MicroRNA profiling in migraine without aura: pilot study. Ann Med. 2015;47(6):468–73. https://doi.org/10.3109/07853890.2015.1071871.
Cheng CY, Chen SP, Liao YC, Fuh JL, Wang YF, Wang SJ. Elevated circulating endothelial-specific microRNAs in migraine patients: a pilot study. Cephalalgia. 2018;38(9):1585–91. https://doi.org/10.1177/0333102417742375.
Andersen HH, Duroux M, Gazerani P. Serum microRNA signatures in migraineurs during attacks and in pain-free periods. Mol Neurobiol. 2016;53(3):1494–500. https://doi.org/10.1007/s12035-015-9106-5.
Sakai A, Suzuki H. microRNA and pain. Adv Exp Med Biol. 2015;888:17–39. https://doi.org/10.1007/978-3-319-22671-2_3.
Sakai A, Suzuki H. Emerging roles of microRNAs in chronic pain. Neurochem Int. 2014;77:58–67. https://doi.org/10.1016/j.neuint.2014.05.010.
Odell DW. Epigenetics of pain mediators. Curr Opin Anesthesiol. 2018;31(4):402–6. https://doi.org/10.1097/Aco.0000000000000613.
Andersen HH, Gazerani P. MicroRNAs and pain. In: Ruberti F, editor. Mapping of nervous system diseases via MicroRNAs. Frontiers in neurotherapeutics series. Boca Raton: CRC; 2016. p. 181–202.
Kress M, Huttenhofer A, Landry M, Kuner R, Favereaux A, Greenberg D, et al. microRNAs in nociceptive circuits as predictors of future clinical applications. Front Mol Neurosci. 2013;6:33. https://doi.org/10.3389/fnmol.2013.00033.
Lutz BM, Bekker A, Tao YX. Noncoding RNAs new players in chronic pain. Anesthesiology. 2014;121(2):409–17. https://doi.org/10.1097/Aln.0000000000000265.
Qureshi RA, Tian Y, McDonald MK, Capasso KE, Douglas SR, Gao R, et al. Circulating microRNA signatures in rodent models of pain. Mol Neurobiol. 2016;53(5):3416–27. https://doi.org/10.1007/s12035-015-9281-4.
Guo JB, Zhu Y, Chen BL, Song G, Peng MS, Hu HY, et al. Network and pathway-based analysis of microRNA role in neuropathic pain in rat models. J Cell Mol Med. 2019;23(7):4534–44. https://doi.org/10.1111/jcmm.14357.
Dai Z, Chu HC, Ma JH, Yan Y, Zhang XY, Liang YX. The regulatory mechanisms and therapeutic potential of microRNAs: from chronic pain to morphine tolerance. Front Mol Neurosci. 2018;11:80. https://doi.org/10.3389/fnmol.2018.00080.
Ramanathan S, Shenoda BB, Ajit SK. Overview of microRNA modulation in analgesic research. Curr Protoc Pharmacol. 2017;79:9.25.1–9.25.10. https://doi.org/10.1002/cpph.29.
Toyama K, Kiyosawa N, Watanabe K, Ishizuka H. Identification of circulating miRNAs differentially regulated by opioid treatment. Int J Mol Sci. 2017;18(9):E1991. https://doi.org/10.3390/ijms18091991.
Kiyosawa N, Watanabe K, Toyama K, Ishizuka H. Circulating miRNA signature as a potential biomarker for the prediction of analgesic efficacy of hydromorphone. Int J Mol Sci. 2019;20(7):1665. https://doi.org/10.3390/ijms20071665.
Kynast KL, Russe OQ, Geisslinger G, Niederberger E. Novel findings in pain processing pathways: implications for miRNAs as future therapeutic targets. Expert Rev Neurother. 2013;13(5):515–25. https://doi.org/10.1586/Ern.13.34.
Niederberger E, Resch E, Parnham MJ, Geisslinger G. Drugging the pain epigenome. Nat Rev Neurol. 2017;13(7):434–47. https://doi.org/10.1038/nrneurol.2017.68.
Andersen HH, Duroux M, Gazerani P. MicroRNAs as modulators and biomarkers of inlammatory and neuropathic pain conditions. Neurobiol Dis. 2014;71:159–68. https://doi.org/10.1016/j.nbd.2014.08.003
Bjersing JL, Lundborg C, Bokarewa MI, Mannerkorpi K. Profile of cerebrospinal microRNAs in fibromyalgia. PLoS ONE. 2013;8(10):e78762. https://doi.org/10.1371/journal.pone.0078762.
Zhou Q, Souba WW, Croce CM, Verne GN. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut. 2010;59(6):775–84. https://doi.org/10.1136/gut.2009.181834.
Wang WT, Zhao YN, Han BW, Hong SJ, Chen YQ. Circulating microRNAs identified in a genome-wide serum microRNA expression analysis as noninvasive biomarkers for endometriosis. J Clin Endocrinol Metab. 2013;98(1):281–9. https://doi.org/10.1210/jc.2012-2415.
Beyer C, Zampetaki A, Lin NY, Kleyer A, Perricone C, Iagnocco A, et al. Signature of circulating microRNAs in osteoarthritis. Ann Rheum Dis. 2015;74(3):e18. https://doi.org/10.1136/annrheumdis-2013-204698.
Tao ZY, Xue Y, Li JF, Traub RJ, Cao DY. Do microRNAs modulate visceral pain? Biomed Res Int. 2018;2018:5406973. https://doi.org/10.1155/2018/5406973.
Birklein F, Ajit SK, Goebel A, Perez R, Sommer C. Complex regional pain syndrome—phenotypic characteristics and potential biomarkers. Nat Rev Neurol. 2018;14(5):272–84. https://doi.org/10.1038/nrneurol.2018.20.
Bjorkman S, Taylor HS. MicroRNAs in endometriosis: biological function and emerging biomarker candidatesdagger. Biol Reprod. 2019;100(5):1135–46. https://doi.org/10.1093/biolre/ioz014.
Filkova M, Jungel A, Gay RE, Gay S. MicroRNAs in rheumatoid arthritis: potential role in diagnosis and therapy. BioDrugs. 2012;26(3):131–41. https://doi.org/10.2165/11631480-000000000-00000.
Chavan SS, Pavlov VA, Tracey KJ. Mechanisms and therapeutic relevance of neuro-immune communication. Immunity. 2017;46(6):927–42. https://doi.org/10.1016/j.immuni.2017.06.008.
Ciszek BP, Khan AA, Dang H, Slade GD, Smith S, Bair E, et al. MicroRNA expression profiles differentiate chronic pain condition subtypes. Transl Res. 2015;166(6):706–20. https://doi.org/10.1016/j.trsl.2015.06.008.
Hwang CK, Wagley Y, Law PY, Wei LN, Loh HH. MicroRNAs in opioid pharmacology. J Neuroimmune Pharmacol. 2012;7(4):808–19. https://doi.org/10.1007/s11481-011-9323-2.
Li MP, Hu YD, Hu XL, Zhang YJ, Yang YL, Jiang C, et al. miRNAs and miRNA polymorphisms modify drug response. Int J Environ Res Public Health. 2016;13(11):E1096. https://doi.org/10.3390/ijerph13111096.
Willemen HLDM, Huo XJ, Mao-Ying QL, Zijlstra J, Heijnen CJ, Kavelaars A. MicroRNA-124 as a novel treatment for persistent hyperalgesia. J Neuroinflamm. 2012;9:143. https://doi.org/10.1186/1742-2094-9-143.
Baumann V, Winkler J. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem. 2014;6(17):1967–84. https://doi.org/10.4155/fmc.14.116.
Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007;4(9):721–6. https://doi.org/10.1038/nmeth1079.
Bors LA, Erdo F. Overcoming the blood-brain barrier. Challenges and tricks for CNS drug delivery. Sci Pharm. 2019;87(1):6. https://doi.org/10.3390/scipharm87010006.
Wen MM. Getting miRNA therapeutics into the target cells for neurodegenerative diseases: a mini-review. Front Mol Neurosci. 2016;9:129. https://doi.org/10.3389/fnmol.2016.00129.
Simion V, Nadim WD, Benedetti H, Pichon C, Morisset-Lopez S, Baril P. Pharmacomodulation of microRNA expression in neurocognitive diseases: obstacles and future opportunities. Curr Neuropharmacol. 2017;15(2):276–90. https://doi.org/10.2174/1570159x14666160630210422.
Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V, Bansal P. MicroRNA therapeutics: discovering novel targets and developing specific therapy. Perspect Clin Res. 2016;7(2):68–74. https://doi.org/10.4103/2229-3485.179431.
Luchting B, Heyn J, Hinske LC, Azad SC. Expression of miRNA-124a in CD4 cells reflects response to a multidisciplinary treatment program in patients with chronic low back pain. Spine (Phila Pa 1976). 2017;42(4):E226–E33. https://doi.org/10.1097/BRS.0000000000001763.
Andersen HH, Gazerani P, Duroux M. EHMTI-0122. Serum micrornas as potential biomarkers of migraine. J Headache Pain. 2014;15(Suppl 1):F1.
Vila-Pueyo M, Fernandez-Morales J, Torres-Ferrus M, Alvarez-Sabin J, Pozo-Rosich P. Lack of differences in microrna expression profiles of blood cells in migraine [abstract no. EHMTI-0361]. J Headache Pain. 2014;15:H3. https://doi.org/10.1186/1129-2377-15-S1-H3.
Migraine Research Foundation. Final report: microRNA Expression Profile in Migraine: the microMIG study. New York: Migraine Research Foundation; 2019. https://migraineresearchfoundation.org/researchers/patricia-pozo-rosich-md-phd/. Accessed 24 Sep 2019.
Tana C, Santilli F, Martelletti P, di Vincenzo A, Cipollone F, Davi G, et al. Correlation between migraine severity and cholesterol levels. Pain Pract. 2015;15(7):662–70. https://doi.org/10.1111/papr.12229.
Tana C, Tafuri E, Tana M, Martelletti P, Negro A, Affaitati G, et al. New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters? J Headache Pain. 2013;14:9. https://doi.org/10.1186/1129-2377-14-9.
Varma A, Jain S, Majid A, De Felice M. Central and peripheral processes in headache. Curr Opin Support Pa. 2018;12(2):142–7. https://doi.org/10.1097/Spc.0000000000000336.
Olesen J, Burstein R, Ashina M, Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol. 2009;8(7):679–90. https://doi.org/10.1016/S1474-4422(09)70090-0.
Panerai AE. Is migraine a disorder of the central nervous system? Neurol Sci. 2013;34(1):S33–5. https://doi.org/10.1007/s10072-013-1363-3.
Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622. https://doi.org/10.1152/physrev.00034.2015.
Peng KP, May A. Migraine understood as a sensory threshold disease. Pain. 2019;160(7):1494–501. https://doi.org/10.1097/j.pain.0000000000001531.
Perry CJ, Blake P, Buettner C, Papavassiliou E, Schain AJ, Bhasin MK, et al. Upregulation of inflammatory gene transcripts in periosteum of chronic migraineurs: implications for extracranial origin of headache. Ann Neurol. 2016;79(6):1000–13. https://doi.org/10.1002/ana.24665.
Burstein R, Perry C, Blake P, Buettner C, Bhasin M. Abnormal expression of gene transcripts linked to inflammatory response in the periosteum of chronic migraine patients: implications to extracranial origin of headache [abstract no. EHMTI-0354]. J Headache Pain. 2014;15:K2. https://doi.org/10.1186/1129-2377-15-S1-K2.
Wei Y, Nazari-Jahantigh M, Chan L, Zhu M, Heyll K, Corbalan-Campos J, et al. The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis. Circulation. 2013;127(15):1609–19. https://doi.org/10.1161/CIRCULATIONAHA.112.000736.
Rukov JL, Vinther J, Shomron N. Pharmacogenomics genes show varying perceptibility to microRNA regulation. Pharmacogenet Genom. 2011;21(5):251–62. https://doi.org/10.1097/FPC.0b013e3283438865.
Fabbri M, Paone A, Calore F, Galli R, Croce CM. A new role for microRNAs, as ligands of Toll-like receptors. RNA Biol. 2013;10(2):169–74. https://doi.org/10.4161/rna.23144.
Park CK, Xu ZZ, Berta T, Han QJ, Chen G, Liu XJ, et al. Extracellular microRNAs activate nociceptor neurons to elicit pain via TLR7 and TRPA1. Neuron. 2014;82(1):47–54. https://doi.org/10.1016/j.neuron.2014.02.011.
Fatima F, Nawaz M. Vesiculated long non-coding RNAs: offshore packages deciphering trans-regulation between cells, cancer progression and resistance to therapies. Noncoding RNA. 2017;3(1). https://doi.org/10.3390/ncrna3010010.
Cannataro R, Perri M, Caroleo MC, Gallelli L, Sarro G, Cione E. Modulation of microRNAs linked to pain-migraine by ketogenic diet [abstract no. P14-007-19]. Curr Dev Nutr. 2019;3(Suppl 1):nzz052.P14-007-19. https://doi.org/10.1093/cdn/nzz052.P14-007-19.
Malhotra R. Understanding migraine: potential role of neurogenic inflammation. Ann Indian Acad Neurol. 2016;19(2):175–82. https://doi.org/10.4103/0972-2327.182302.
Ramachandran R. Neurogenic inflammation and its role in migraine. Semin Immunopathol. 2018;40(3):301–14. https://doi.org/10.1007/s00281-018-0676-y.
Albrecht DS, Mainero C, Ichijo E, Ward N, Granziera C, Zurcher NR, et al. Imaging of neuroinflammation in migraine with aura: a [(11)C]PBR28 PET/MRI study. Neurology. 2019;92(17):e2038–50. https://doi.org/10.1212/WNL.0000000000007371.
Spierings EL. Spreading depression, neurogenic inflammation, and the parallel theory of migraine pathogenesis. Headache. 2001;41(9):911–3.
Lewis DW. Pediatric migraine. Neurol Clin. 2009;27(2):481–501. https://doi.org/10.1016/j.ncl.2008.11.003.
Torriero R, Capuano A, Mariani R, Frusciante R, Tarantino S, Papetti L, et al. Diagnosis of primary headache in children younger than 6 years: a clinical challenge. Cephalalgia. 2017;37(10):947–54. https://doi.org/10.1177/0333102416660533.
Papetti L, Ursitti F, Moavero R, Ferilli MAN, Sforza G, Tarantino S, et al. prophylactic treatment of pediatric migraine: is there anything new in the last decade? Front Neurol. 2019;10:771. https://doi.org/10.3389/fneur.2019.00771.
Gallelli L, Cione E, Peltrone F, Siviglia S, Verano A, Chirchiglia D, et al. Hsa-miR-34a-5p and hsa-miR-375 as biomarkers for monitoring the effects of drug treatment for migraine pain in children and adolescents: a pilot study. J Clin Med. 2019;8(7):928. https://doi.org/10.3390/jcm8070928.
Chen XH, Li BX, Luo RC, Cai SN, Zhang C, Cao XL. Analysis of the function of microRNA-375 in humans using bioinformatics. Biomed Rep. 2017;6(5):561–6. https://doi.org/10.3892/br.2017.889.
Ferroni P, Barbanti P, Spila A, Fratangeli F, Aurilia C, Fofi L, et al. Circulating biomarkers in migraine. New opportunities for precision medicine. Curr Med Chem. Epub 2018 Jun 22. https://doi.org/10.2174/0929867325666180622122938.
Wang JY, Li H, Ma CM, Wang JL, Lai XS, Zhou SF. MicroRNA profiling response to acupuncture therapy in spontaneously hypertensive rats. Evid Based Compl Alternat Med. 2015;2015:204367. https://doi.org/10.1155/2015/204367.
Fehlmann T, Ludwig N, Backes C, Meese E, Keller A. Distribution of microRNA biomarker candidates in solid tissues and body fluids. RNA Biol. 2016;13(11):1084–8. https://doi.org/10.1080/15476286.2016.1234658.
Jasim H, Carlsson A, Hedenberg-Magnusson B, Ghafouri B, Ernberg M. Saliva as a medium to detect and measure biomarkers related to pain. Sci Rep. 2018;8:3220. https://doi.org/10.1038/s41598-018-21131-4.
Johnson JJ, Loeffert AC, Stokes J, Olympia RP, Bramley H, Hicks SD. Association of salivary microRNA changes with prolonged concussion symptoms. JAMA Pediatr. 2018;172(1):65–73. https://doi.org/10.1001/jamapediatrics.2017.3884.
Hicks SD. Saliva: a new tool for concussion diagnosis? NeurologyTimes. 2018. https://www.neurologytimes.com/tbi/saliva-new-tool-concussion-diagnosis. Accessed 20 Jul 2019.
Michlewski G, Caceres JF. Post-transcriptional control of miRNA biogenesis. RNA. 2019;25(1):1–16. https://doi.org/10.1261/rna.068692.118.
Dwivedi S, Purohit P, Misra R, Pareek P, Goel A, Khattri S, et al. Diseases and molecular diagnostics: a step closer to precision medicine. Indian J Clin Biochem. 2017;32(4):374–98. https://doi.org/10.1007/s12291-017-0688-8.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Parisa Gazerani is the head of research at EMProS bio, and the scientific consultant for BalancAir, both of which are companies that focus their interest on migraine.
Funding
The author has no funding to report in relation to this article.
Rights and permissions
About this article
Cite this article
Gazerani, P. Current Evidence on Potential Uses of MicroRNA Biomarkers for Migraine: From Diagnosis to Treatment. Mol Diagn Ther 23, 681–694 (2019). https://doi.org/10.1007/s40291-019-00428-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40291-019-00428-8